Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Terumo Corporation (4543.T)
Tokyo, JP
Terumo Corporation is a global enterprise dedicated to the development, manufacturing, and distribution of a wide array of medical products and equipment. Its comprehensive operations are structured across three primary divisions: the Cardiac and Vascular Company, the Medical Care Solutions Company, and the Blood and Cell Technologies Company. The Cardiac and Vascular Company focuses on cardiovascular and neurovascular interventions. Its product portfolio encompasses a variety of devices, including angiographic guidewires, catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, and self-expanding peripheral stents, alongside advanced intravascular ultrasound systems and imaging catheters. This division also develops specialized devices for treating cerebral aneurysms, such as coils, stents, and intrasaccular devices, as well as embolization systems, aspiration catheters, and clot retrievers for ischemic stroke. Furthermore, it supplies critical components for cardiac surgery, including oxygenators and cardio-pulmonary bypass systems, in addition to artificial vascular and stent grafts. The Medical Care Solutions Company addresses a broad spectrum of general medical and patient care needs. Offerings include essential medical supplies like syringes, infusion and syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, and products for pain management and nutritional support, as well as adhesion barriers. This segment also produces consumer health monitoring devices such as blood glucose monitoring systems, disposable needles for pen-injectors, insulin patch pumps, blood pressure monitors, and digital thermometers. Moreover, it provides contract manufacturing services for pharmaceutical companies, specializing in prefilled syringes and devices like prefillable syringes and needles for pharmaceutical packaging. Finally, the Blood and Cell Technologies Company concentrates on products and systems for blood and cell management. Its offerings span blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, and advanced cell expansion systems. Established in 1921, the company was initially known as Sekisen Ken-onki Corporation before adopting its current name, Terumo Corporation, in October 1974. Terumo Corporation maintains its corporate headquarters in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.05% | +17.80% | +5.89% | +16.87% | -1.62% | +1.79% | -14.86% | +11.88% | +15.12% | +112.01% | +1,105.76% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 9 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+9.2% ★ Q1'26: +13.8% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+16.6% ★ Q1'26: +43.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+11.9% Q1'26: +17.9% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+16.3% ★ Q1'26: +11.4% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+8.4% ★ Q1'26: +6.8% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.4% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×1.36× Q1'26: 1.57× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 13 Rev. Ana. 13 EPS Ana. |
Mar 2027 12 Rev. Ana. 4 EPS Ana. |
Mar 2028 11 Rev. Ana. 11 EPS Ana. |
Mar 2029 6 Rev. Ana. 6 EPS Ana. |
Mar 2030 3 Rev. Ana. 2 EPS Ana. |
Mar 2031 2 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
489.51B
est: 492.25B (-0.6%)
|
525.03B
est: 528.19B (-0.6%)
|
514.16B
est: 509.03B (+1.0%)
|
587.78B
est: 590.42B (-0.4%)
|
599.48B
est: 601.20B (-0.3%)
|
628.90B
est: 629.89B (-0.2%)
|
613.84B
est: 607.85B (+1.0%)
|
703.30B
est: 699.55B (+0.5%)
|
820.21B
est: 816.83B (+0.4%)
|
921.86B
est: 964.81B (-4.5%)
|
1.04T
est: 1.03T (+0.9%)
|
1.12T
1.10T – 1.14T
+9.2% YoY
|
1.23T
1.18T – 1.25T
+9.2% YoY
|
1.30T
1.25T – 1.36T
+6.3% YoY
|
1.38T
1.38T – 1.38T
+5.9% YoY
|
1.47T
1.42T – 1.53T
+6.9% YoY
|
1.57T
1.51T – 1.62T
+6.2% YoY
|
| EBITDA |
105.99B
est: 118.24B (-10.4%)
|
122.99B
est: 126.88B (-3.1%)
|
111.48B
est: 122.27B (-8.8%)
|
150.92B
est: 141.82B (+6.4%)
|
148.80B
est: 144.41B (+3.0%)
|
160.65B
est: 151.30B (+6.2%)
|
153.92B
est: 146.01B (+5.4%)
|
174.58B
est: 168.04B (+3.9%)
|
188.44B
est: 196.21B (-4.0%)
|
219.66B
est: 240.08B (-8.5%)
|
242.51B
est: 255.66B (-5.1%)
|
279.26B
274.21B – 282.53B
+9.2% YoY
|
304.84B
294.05B – 311.83B
+9.2% YoY
|
324.19B
310.98B – 339.52B
+6.3% YoY
|
343.17B
342.69B – 343.65B
+5.9% YoY
|
366.73B
352.73B – 379.73B
+6.9% YoY
|
389.43B
374.57B – 403.24B
+6.2% YoY
|
| EBIT |
65.30B
est: 76.60B (-14.8%)
|
78.32B
est: 82.20B (-4.7%)
|
77.01B
est: 79.22B (-2.8%)
|
108.88B
est: 91.88B (+18.5%)
|
104.76B
est: 93.56B (+12.0%)
|
108.29B
est: 98.02B (+10.5%)
|
99.99B
est: 94.59B (+5.7%)
|
115.70B
est: 108.87B (+6.3%)
|
118.20B
est: 127.12B (-7.0%)
|
142.92B
est: 159.76B (-10.5%)
|
157.06B
est: 170.13B (-7.7%)
|
185.83B
182.47B – 188.00B
+9.2% YoY
|
202.85B
195.67B – 207.50B
+9.2% YoY
|
215.72B
206.94B – 225.93B
+6.3% YoY
|
228.36B
228.04B – 228.67B
+5.9% YoY
|
244.03B
234.72B – 252.69B
+6.9% YoY
|
259.14B
249.25B – 268.33B
+6.2% YoY
|
| Net Income |
38.47B
est: 38.84B (-1.0%)
|
50.68B
est: 50.04B (+1.3%)
|
54.23B
est: 49.74B (+9.0%)
|
91.30B
est: 77.40B (+18.0%)
|
79.47B
est: 79.62B (-0.2%)
|
85.21B
est: 82.44B (+3.4%)
|
77.27B
est: 74.79B (+3.3%)
|
88.81B
est: 90.96B (-2.4%)
|
89.33B
est: 89.48B (-0.2%)
|
106.37B
est: 117.72B (-9.6%)
|
116.98B
est: 124.93B (-6.4%)
|
135.91B
124.92B – 151.42B
+8.8% YoY
|
159.97B
153.92B – 161.25B
+17.7% YoY
|
176.04B
164.23B – 195.09B
+10.0% YoY
|
201.90B
188.67B – 213.97B
+14.7% YoY
|
227.75B
216.45B – 238.25B
+12.8% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
159.21B
est: 129.90B (+22.6%)
|
170.05B
est: 139.39B (+22.0%)
|
138.33B
est: 134.33B (+3.0%)
|
157.32B
est: 155.81B (+1.0%)
|
163.90B
est: 158.65B (+3.3%)
|
165.64B
est: 166.22B (-0.4%)
|
160.38B
est: 160.41B (0.0%)
|
178.79B
est: 184.61B (-3.2%)
|
214.92B
est: 215.56B (-0.3%)
|
250.92B
est: 274.08B (-8.5%)
|
279.53B
est: 291.87B (-4.2%)
|
318.80B
313.04B – 322.54B
+9.2% YoY
|
348.01B
335.69B – 355.98B
+9.2% YoY
|
370.10B
355.02B – 387.60B
+6.3% YoY
|
391.77B
391.22B – 392.31B
+5.9% YoY
|
418.66B
402.68B – 433.51B
+6.9% YoY
|
444.58B
427.61B – 460.35B
+6.2% YoY
|
| EPS |
50.67
est: 26.23 (+93.2%)
|
67.57
est: 33.79 (+100.0%)
|
76.16
est: 33.59 (+126.7%)
|
121.03
est: 52.26 (+131.6%)
|
53.50
est: 53.76 (-0.5%)
|
56.98
est: 55.67 (+2.4%)
|
51.16
est: 50.50 (+1.3%)
|
58.72
est: 61.42 (-4.4%)
|
59.50
est: 63.63 (-6.5%)
|
71.50
est: 79.18 (-9.7%)
|
79.01
est: 87.32 (-9.5%)
|
91.25
84.67 – 102.63
+4.5% YoY
|
107.04
104.33 – 109.29
+17.3% YoY
|
120.60
111.31 – 132.23
+12.7% YoY
|
137.88
127.88 – 145.02
+14.3% YoY
|
154.37
146.71 – 161.48
+12.0% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-01 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-15 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hikaru Samejima | Representative Director, President & Chief Executive Officer | 117M | male |
| Toshiaki Takagi | Chairman of the Board & Group Managing Executive Officer | 94M | male |
| Jin Hagimoto | Chief Financial Officer, Chief Information Officer, GM of Accounting, Corporate Planning, Tax, IT Planning Dept. & GBS | — | — |
| Miho Mizuguchi | Executive Officer, Chief Legal Officer and GM of CLO Office, Legal & Compliance Department | — | female |
| Norimasa Kunimoto | Director & Group Managing Executive Officer | — | male |
| Shinji Omori | Chief Technology Officer, Corporate R&D Officer, GM of R&D Center & Executive Officer | — | — |
| Takumi Uchida | Executive Officer & Chief Operating Officer | — | — |
| Tomoko Adachi | Chief Human Resources Officer & Group Executive Officer | — | — |
| Fumihisa Hirose | Group Managing Executive Officer | — | — |
| Toshihiko Nagata | Group Senior Managing Executive Officer & Director | — | male |
| Itaru Sakaguchi | Group Managing Executive Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4543.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
